Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-96673 |
Synonyms | |
Therapy Description |
CC-96673 is a bispecific antibody that targets CD20 with high affinity and CD47 with low affinity and inhibits the interaction of CD47 with SIRPa, which potentially induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against CD20-expressing tumor cells, increases phagocytosis of tumor cells, and inhibits tumor growth (PMID: 38349008). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-96673 | CC 96673|CC96673|BMS-986358|BMS 986358|BMS986358 | CD20 Antibody 25 CD47 Antibody 31 | CC-96673 is a bispecific antibody that targets CD20 with high affinity and CD47 with low affinity and inhibits the interaction of CD47 with SIRPa, which potentially induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against CD20-expressing tumor cells, increases phagocytosis of tumor cells, and inhibits tumor growth (PMID: 38349008). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04860466 | Phase I | CC-96673 | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Terminated | USA | FRA | ESP | CAN | 0 |